These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9054672)

  • 1. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
    Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
    Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).
    Galimberti S; Cervetti G; Cecconi N; Fazzi R; Pacini S; Guerrini F; Manetti C; Caracciolo F; Petrini M
    J Immunother; 2004; 27(5):389-93. PubMed ID: 15314547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
    Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo 'purging' of residual disease in CLL with Campath-1H.
    Dyer MJ; Kelsey SM; Mackay HJ; Emmett E; Thornton P; Hale G; Waldmann H; Newland AC; Catovsky D
    Br J Haematol; 1997 Jun; 97(3):669-72. PubMed ID: 9207420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
    Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
    Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
    Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
    Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
    Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
    Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.
    Alinari L; Lapalombella R; Andritsos L; Baiocchi RA; Lin TS; Byrd JC
    Oncogene; 2007 May; 26(25):3644-53. PubMed ID: 17530018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Cavalli-Björkman N; Osby E; Lundin J; Kalin M; Osterborg A; Gruber A
    Med Oncol; 2002; 19(4):277-80. PubMed ID: 12512923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.